Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a pioneering molecular diagnostics company based in Sandy, Utah. The company is renowned for its unique, patented technology that significantly enhances the speed, performance, and cost-efficiency of DNA testing for a variety of diseases compared to traditional methods. Co-Diagnostics focuses on the development, manufacturing, and commercialization of its proprietary technologies through sales, development, and licensing agreements.
Co-Diagnostics’ core technology is protected by multiple patents and trade secrets, enabling revolutionary approaches in molecular diagnostics. These innovations have been utilized to develop a range of assays in the infectious disease sector, demonstrating the technology's exceptional capabilities. The company's patented inventions stem from advanced mathematical models designed by Dr. Brent C. Satterfield.
The firm’s product portfolio includes diagnostic tests for diseases such as tuberculosis, Zika, hepatitis B and C, malaria, dengue, and HIV. These tests utilize the detection and analysis of nucleic acid molecules (DNA or RNA) to provide accurate and efficient diagnostics. Co-Diagnostics also leverages its proprietary technology to create tests for its Co-Dx PCR platform, which includes at-home and point-of-care solutions.
One of the notable collaborations of Co-Diagnostics is its joint venture with CoSara Diagnostics Pvt Ltd in India. This partnership has led to regulatory clearance from India’s Central Drugs Standard Control Organization (CDSCO) for multiple diagnostic tests, including the SARAPLEX™ Influenza Multiplex (IFM) Test Kit, which differentiates between Influenza A and B strains.
Recently, Co-Diagnostics announced significant milestones, such as the opening of new manufacturing facilities in Salt Lake City, Utah, and Ranoli, India. These facilities will enhance the production of the company’s novel Co-Dx PCR Pro™ instrument and test cups, as well as the Co-Primers™ chemistry that is vital for its PCR diagnostic tests. The Salt Lake City facility, inaugurated with support from local dignitaries and business leaders, marks a critical step in expanding the company's production capabilities.
The company’s forward-looking strategies include submitting an Emergency Use Authorization (EUA) to the FDA for the Co-Dx PCR Pro™ instrument, mobile app, and COVID-19 test. This submission is part of Co-Diagnostics’ effort to decentralize PCR diagnostics and extend its reach to at-home and point-of-care settings. The company is also developing tests for tuberculosis, multiplex respiratory infections, and HPV, among others.
Co-Diagnostics’ financial performance and strategic initiatives are regularly discussed through conference calls and webcasts, involving key executives such as CEO Dwight Egan and CFO Brian Brown. The company remains committed to innovation and growth, aiming to provide accessible and high-quality diagnostic solutions worldwide.
SALT LAKE CITY, Aug. 31, 2022 /PRNewswire/ -- Co-Diagnostics (Nasdaq: CODX) will showcase its innovative molecular diagnostics at Medical Fair Asia 2022 from August 31 to September 2 in Singapore. This premier medical trade fair is expected to attract over 14,000 visitors from 70 countries, offering Co-Dx an opportunity to strengthen its distributor outreach and connect with international customers. Attendees can learn more about Co-Diagnostics’ products, including its point-of-care PCR diagnostics, at Booth #2G01.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) is set to sponsor, present, and host a booth at the 14th Annual Next Generation Dx Summit from August 22-24 in Washington, D.C.. The summit focuses on advancements in point-of-care, infectious disease, and liquid biopsy diagnostics. CEO Dwight Egan will present the upcoming Co-Dx PCR Home platform on August 22 at 12:15 PM ET. In-person attendees can visit the Company at Booth #206. For more details on the summit, visit Next Generation Dx.
Co-Diagnostics, Inc. (NASDAQ: CODX) released its second quarter 2022 financial results, reporting a revenue decline to $5.0 million from $27.4 million year-over-year, primarily due to decreased demand for its Logix Smart™ COVID-19 Test. The company faced an operating loss of $4.1 million, contrasting with a prior year operating income of $11.8 million. Net loss registered at $2.7 million, or $0.08 per share. Despite these challenges, Co-Diagnostics continues to progress on the Co-Dx PCR Home platform and expand its product offerings, including tests for monkeypox.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its participation in the Yale School of Public Health SalivaDirect™ Conference on July 28-29 in Chicago. The conference focuses on promoting saliva-based testing for infectious diseases. CEO Dwight Egan and Chairman of the Scientific Advisory Board Dr. Carl Wittwer will present on the topic "The Opportunity for A New Global Response To Infectious Disease" on July 29th at 3:00 PM CT. Co-Diagnostics specializes in molecular diagnostics, developing advanced technologies for testing infectious diseases and genetic markers.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced a global expansion of its OEM agreement with Bio Molecular Systems (BMS) during its update at AACC. This expanded agreement increases Co-Dx's approved sales territories to 193 countries, building on existing sales in over 50 countries. BMS, known for its expertise in PCR technology, manufactures the Co-Dx Box™, enhancing the user experience of Co-Diagnostics' molecular assays. CEO Dwight Egan expressed optimism about the growth opportunities this collaboration presents for expanding the reach of their affordable and high-quality molecular testing tools.
Co-Diagnostics, Inc. (Nasdaq: CODX) will showcase its diagnostics products at the AACC Annual Scientific Meeting & Clinical Lab Expo from July 24-28 in Chicago, IL. The Company invites distributors and customers for a global update on July 26 at 11 am CT in room S103A. CEO Dwight Egan will present on the Co-Dx PCR Home testing platform at 2 pm CT on July 26. Co-Dx has sold over 34 million PCR tests across more than 50 countries. The Co-Dx PCR Home testing platform is under FDA review and not yet available for sale.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced the shipment of testing reagents for monkeypox virus to an international distributor amidst a global outbreak. As of July 7, 2022, over 6,000 monkeypox cases have been reported across 59 countries, according to the World Health Organization. The reagents were developed quickly to meet urgent regional demands. CEO Dwight Egan emphasized the importance of their PCR-based testing products for effective disease detection, underscoring the company's commitment to high-quality, affordable diagnostics worldwide.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its presentation at the 29th International Biodetection Technologies Conference, held virtually on June 28-29, 2022. CEO Dwight Egan will discuss the upcoming PCR Home testing platform during the Point-of-Care Diagnostics agenda on June 29 at 12:30 pm ET. This conference focuses on the latest innovations in the detection and identification of biological threats. An archived version of the presentation will be available on the company's website post-conference.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that key executives will participate in the Sidoti Summer Small Cap Virtual Investor Conference on June 15-16, 2022. CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson will present and hold one-on-one meetings with investors. The presentation starts at 3:15 p.m. EDT on June 15 and can be accessed via the company's website. Co-Diagnostics specializes in molecular diagnostics, focusing on developing tests that analyze nucleic acid molecules for various applications, including infectious diseases.
Co-Diagnostics, Inc. (Nasdaq: CODX) is participating in the 22nd MEDEXPO Africa 2022 in Nairobi, Kenya from June 9-11. This significant event showcases over 30 countries' medical technology solutions, aiming at buyers seeking innovative products and services. This marks Co-Dx's first trade show in Africa, enhancing its initiative to promote COVID-19 and other infectious disease tests across the continent. Notably, the company has completed the design of a PCR test for monkeypox. Interested attendees can find Co-Dx at Booth #124.
FAQ
What is the current stock price of Co-Diagnostics (CODX)?
What is the market cap of Co-Diagnostics (CODX)?
What does Co-Diagnostics, Inc. specialize in?
Where is Co-Diagnostics headquartered?
What diseases can Co-Diagnostics' tests diagnose?
What is the Co-Dx PCR platform?
What recent achievements has Co-Diagnostics made?
What is the CoSara Diagnostics joint venture?
What are Co-Primers?
What regulatory clearances has Co-Diagnostics received in India?
What is the FDA status of Co-Diagnostics' products?
Who are the key executives at Co-Diagnostics?
